knowledge -WSS

knowledge

author：Wikipedia 2025-09-06 01:58:41 - browse：8786

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Ukraine seeks to reclaim its role as a hub for clinical trials

knowledge

focus

WSS

Humana, CVS hope to turn members into patients at clinics

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

What Mike Pence has said that could be used in a Donald Trump trial

For BCIs, commercial hurdles may be bigger than scientific ones

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Researchers tackle phage therapy hurdles for wider adoption

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Activists slam private health insurers over coverage restrictions

Microsoft strikes partnership with Duke Health to advance health AI

As demand for Covid shots wanes, Moderna seeks its next success

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Anesthesiologist group: stop taking Ozempic before surgery

Surprise medical billing ban raises prices elsewhere

In Memoriam: Notable people who died in 2023

The drug industry sees a key ally in the Senate prevail

The cancer drug shortage isn’t new — and neither are the solutions

Abridge raises $150m as clinical notes automation market heats up

focus

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

ProMED, early warning system on disease outbreaks, in peril

Gilgo Beach: Police identify another victim in serial killing investigation

Hospitals are piloting generative AI tools as regulators play catch

Opioid cravings were reduced by anti

Microsoft strikes partnership with Duke Health to advance health AI

hotspot

knowledge

focus

explore